Available now: Building an Investable IP Portfolio Whitepaper
​

European Pharmaceutical Review: Compulsory licenses in Germany

No items found.
​
11 March 2019
Tags
Litigation
Life
Table of contents
  • Toc Heading
  • Toc Heading

Head of EIP’s Düsseldorf office, Christof Höhne, outlines the implications of Germany’s compulsory licensing in an article for the latest issue of the European Pharmaceutical Review. Two recent, high-profile pharmaceutical cases which have set the course for the future of German IP law are analysed by Christof, who highlights the advantages and disadvantages faced by both parties in a licensing negotiation.

The article can be read on the European Pharmaceutical Review website here.

Related articles

See all articles

Five EIP partners named among the world's leading IP strategists in the 2026 IAM Strategy 300
17 August 2026
Christof Höhne, Darren Smyth, Heather McCann, James Seymour, and Sebastian Fuchs have all been named in this year's list, each recognised for their own approach to building patent value for clients.
​
Stuart Malcolm joins EIP as Partner, Solicitor, strengthening EIP's Commercial practice
17 June 2026
EIP is delighted to announce that Stuart Malcolm has joined EIP as a Partner, Solicitor on 17 June 2026, strengthening our Commercial practice. Stuart brings more than 25 years of experience as a commercial and intellectual property lawyer, with a career spanning private practice, senior in-house leadership, and the United Kingdom's deep tech and innovation sectors.
​
EIP named one of Europe's leading patent firms for the eighth year running, with gold in five sectors
16 June 2026
EIP has again been named one of Europe's leading patent law firms by the Financial Times. In its 2026 ranking, EIP earned gold in five of the six technology sectors, and silver in the sixth, Materials and Nanotechnology. It is the eighth year running the firm has featured, every year since the ranking began in 2019.
​